NorthRock Partners LLC Sells 195 Shares of Humana Inc. (NYSE:HUM)

by · The Cerbat Gem

NorthRock Partners LLC lowered its stake in Humana Inc. (NYSE:HUM – Free Report) by 22.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 673 shares of the insurance provider’s stock after selling 195 shares during the period. NorthRock Partners LLC’s holdings in Humana were worth $213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HUM. Norden Group LLC lifted its position in Humana by 137.9% in the first quarter. Norden Group LLC now owns 1,130 shares of the insurance provider’s stock worth $392,000 after buying an additional 655 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. bought a new stake in shares of Humana in the 1st quarter worth about $12,607,000. Duality Advisers LP boosted its stake in shares of Humana by 58.3% during the 1st quarter. Duality Advisers LP now owns 19,182 shares of the insurance provider’s stock worth $6,651,000 after purchasing an additional 7,068 shares during the period. Empirical Finance LLC grew its holdings in Humana by 3.4% during the 1st quarter. Empirical Finance LLC now owns 4,543 shares of the insurance provider’s stock valued at $1,575,000 after purchasing an additional 148 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. raised its position in Humana by 137.6% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,801 shares of the insurance provider’s stock worth $1,665,000 after purchasing an additional 2,780 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Up 10.8 %

Shares of Humana stock opened at $288.69 on Thursday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $34.76 billion, a P/E ratio of 25.57, a PEG ratio of 1.98 and a beta of 0.52. The firm’s 50 day moving average price is $291.98 and its 200-day moving average price is $333.24. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $527.18.

Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, sell-side analysts predict that Humana Inc. will post 16.15 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.23%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Analyst Ratings Changes

Several brokerages have issued reports on HUM. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 target price on shares of Humana in a research report on Tuesday, October 1st. Barclays boosted their price objective on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. TD Cowen increased their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday. Piper Sandler lowered shares of Humana from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Finally, Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and reduced their price target for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Twenty research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus price target of $315.86.

Get Our Latest Report on HUM

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories